C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, announced that it has entered into an exclusive license and collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.